

Resource Summary Report

Generated by [RRID](#) on Aug 17, 2026

pVITRO1-Trastuzumab-IgG1/?

RRID:Addgene_61883

Type: Plasmid

Proper Citation

RRID:Addgene_61883

Plasmid Information

URL: <http://www.addgene.org/61883>

Proper Citation: RRID:Addgene_61883

Insert Name: HER2/neu receptor specific humanized Gamma 1 heavy chain expression cassette

Organism: Homo sapiens

Bacterial Resistance: Hygromycin

Defining Citation: [PMID:25073855](#)

Vector Backbone Description: Backbone Marker:InvivoGen; Backbone Size:6491; Vector Backbone:pVITRO1-hygro-mcs; Vector Types:Mammalian Expression; Bacterial Resistance:Hygromycin

Plasmid Name: pVITRO1-Trastuzumab-IgG1/?

Record Creation Time: 20220422T222355+0000

Record Last Update: 20260815T081747+0000

Ratings and Alerts

No rating or validation information has been found for pVITRO1-Trastuzumab-IgG1/?.

No alerts have been found for pVITRO1-Trastuzumab-IgG1/?.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang W, et al. (2025) Engineering affinity-matured variants of an anti-polysialic acid monoclonal antibody with superior cytotoxicity-mediating potency. *bioRxiv : the preprint server for biology*.

Qiu Z, et al. (2025) N-Terminal Conjugation of a Near-Infrared Photosensitizer to an Antibody for Cancer Diagnosis and Treatment. *ACS omega*, 10(24), 25596.

Wang W, et al. (2025) Engineering affinity-matured variants of an anti-polysialic acid monoclonal antibody with superior cytotoxicity-mediating potency. *Cell chemical biology*, 32(8), 1042.

Gebel J, et al. (2025) Potent optogenetic regulation of gene expression in mammalian cells for bioproduction and basic research. *Nucleic acids research*, 53(12).

Bednova O, et al. (2025) Integrating Biochemical and Computational Approaches Reveal Structural Insights in Trastuzumab scFv-Fc Antibody Engineering. *Biomolecules*, 15(5).

Ren J, et al. (2024) Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-V α 2+ T cell malignancy. *Nature communications*, 15(1), 519.

Reis-Claro I, et al. (2024) Application of the iPLUS non-coding sequence in improving biopharmaceuticals production. *Frontiers in bioengineering and biotechnology*, 12, 1355957.

Özçelik CE, et al. (2024) Screening Peptide Drug Candidates To Neutralize Whole Viral Agents: A Case Study with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *ACS pharmacology & translational science*, 7(4), 1032.

Yu B, et al. (2022) Engineered cell entry links receptor biology with single-cell genomics. *Cell*, 185(26), 4904.

Zinngrebe J, et al. (2022) Compound heterozygous variants in OTULIN are associated with fulminant atypical late-onset ORAS. *EMBO molecular medicine*, 14(3), e14901.

Jaroentomeechai T, et al. (2022) A universal glycoenzyme biosynthesis pipeline that enables efficient cell-free remodeling of glycans. *Nature communications*, 13(1), 6325.

Kraivong R, et al. (2021) A simple approach to identify functional antibody variable genes in murine hybridoma cells that coexpress aberrant kappa light transcripts by restriction enzyme digestion. *Asian Pacific journal of allergy and immunology*, 39(4), 287.

Cruz E, et al. (2021) Glycan Profile Analysis of Engineered Trastuzumab with Rationally Added Glycosylation Sequons Presents Significantly Increased Glycan Complexity. *Pharmaceutics*, 13(11).

Sun T, et al. (2020) Development of a Proline-Based Selection System for Reliable Genetic Engineering in Chinese Hamster Ovary Cells. *ACS synthetic biology*, 9(7), 1864.

Natarajan A, et al. (2020) Engineering orthogonal human O-linked glycoprotein biosynthesis in bacteria. *Nature chemical biology*, 16(10), 1062.

Reslan M, et al. (2020) Enhancing the stability of adalimumab by engineering additional glycosylation motifs. *International journal of biological macromolecules*, 158, 189.

Zhou F, et al. (2019) High-Affinity Antibody Detection with a Bivalent Circularized Peptide Containing Antibody-Binding Domains. *Biotechnology journal*, 14(5), e1800647.

Cox EC, et al. (2019) Antibody-Mediated Endocytosis of Polysialic Acid Enables Intracellular Delivery and Cytotoxicity of a Glycan-Directed Antibody-Drug Conjugate. *Cancer research*, 79(8), 1810.

Elgundi Z, et al. (2017) Laboratory Scale Production and Purification of a Therapeutic Antibody. *Journal of visualized experiments : JoVE*(119).

Stengl A, et al. (2017) A Simple and Sensitive High-Content Assay for the Characterization of Antiproliferative Therapeutic Antibodies. *SLAS discovery : advancing life sciences R & D*, 22(3), 309.